Surface Competitors

Delisted . USA . 
Stock . Surface Oncology
SURFDelisted Stock  USD 0.96  0.03  3.23%   
Surface Oncology competes with Syros Pharmaceuticals, Repare Therapeutics, Personalis, Evogene, and Iovance Biotherapeutics; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Surface Oncology competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Surface Oncology to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Surface Oncology competition on your existing holdings.
  
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.960.960.96
Details
Intrinsic
Valuation
LowRealHigh
0.750.751.06
Details
Naive
Forecast
LowNextHigh
0.870.870.87
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
0.950.960.97
Details

Surface Oncology Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Surface Oncology and its competitors represents the degree of relationship between the price movements of corresponding delisted stocks. A correlation of about +1.0 implies that the price of Surface and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Surface Oncology does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
EVGN
+ 0.74
PSNL
RPTX
+ 0.68
SYRS
IOVA
+ 0.6
PSNL
IOVA
+ 0.59
SYRS
PSNL
+ 0.5
SYRS
IOVA
+ 0.42
EVGN
  
High negative correlations   
EVGN
- 0.24
RPTX

Risk-Adjusted Indicators

There is a big difference between Surface Stock performing well and Surface Oncology Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Surface Oncology's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
All Fundamental Data

Surface Oncology Competitive Analysis

The better you understand Surface Oncology competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Surface Oncology's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Surface Oncology's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
SURF SYRS RPTX PSNL EVGN IOVA
 3.23 
 0.96 
Surface
 11.54 
 0.29 
Syros
 5.39 
 2.81 
Repare
 2.66 
 3.47 
Personalis
 1.25 
 1.62 
Evogene
 3.76 
 8.55 
Iovance
Market Volatility
(90 Days Market Risk)
Very steady
Dangerous
Slightly risky
Risky
Dangerous
Somewhat reliable
Market Performance
(90 Days Performance)
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
Dangerous
High
Low
Quite High
Very High
Low
Current Valuation
(Equity Enterprise Value)
Over Valued
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Hold
Strong Buy
Strong Buy
Strong Buy
Strong Buy
Trade Advice
(90 Days Macroaxis Advice)
Not Rated
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Sell
Current Ratio
8.19 X
6.57 X
7.35 X
6.26 X
6.80 X
6.72 X
Net Asset
159.91 M
168.17 M
253.9 M
225.1 M
51.1 M
780.35 M
Profit Margin
N/A
N/A
(1.26) %
(1.05) %
(2.10) %
N/A
EBITDA
(61.87 M)
(157.19 M)
(114.27 M)
(96.81 M)
(23.2 M)
(427.43 M)
Current Valuation
18.31 M
9.82 M
(57.41 M)
140.3 M
(945.11 K)
2.29 B
Price To Book
0.47 X
10.65 X
0.72 X
1.43 X
2.83 X
3.37 X
Operating Margin
N/A
(288.92) %
(1.39) %
(0.56) %
(6.67) %
(1.52) %
Retained Earnings
(204.33 M)
(722.81 M)
(333.11 M)
(468.71 M)
(257.59 M)
(2.01 B)
Current Asset
22 K
85.51 M
N/A
N/A
104.38 M
290.82 M
Beta
1.75
1.59
0.71
1.95
1.08
0.59
Number Of Employees
35
68
179
223
142
557
Shares Outstanding
60.82 M
26.83 M
42.51 M
70.65 M
5.37 M
304.78 M
Cash Flow From Operations
(59.55 M)
(109.71 M)
(127.16 M)
(56.26 M)
(21.58 M)
(361.82 M)
Total Debt
56.04 M
62.08 M
3.41 M
48.96 M
11.51 M
75.86 M
Return On Equity
-1.06
-7.77
-0.41
-0.58
-0.82
-0.57
Z Score
-1.33
N/A
N/A
N/A
N/A
N/A
Return On Asset
-0.41
-0.6
-0.23
-0.19
-0.28
-0.29
Number Of Shares Shorted
165.27 K
1.25 M
749.74 K
3.24 M
22.35 K
59.73 M
Book Value Per Share
0.81 X
(0.41) X
4.12 X
2.36 X
2.38 X
2.54 X
Current Liabilities
36 K
9.57 M
N/A
N/A
5.64 M
10.12 M
Total Asset
159.91 M
168.17 M
253.9 M
225.1 M
51.1 M
780.35 M
Debt To Equity
0.45 %
0.49 %
0.03 %
0.22 %
0.05 %
0.17 %
Short Ratio
0.45 X
3.20 X
6.38 X
6.88 X
0.04 X
13.08 X
Target Price
2.38
1.0
12.5
7.02
10.0
23.77
Shares Owned By Institutions
46.03 %
75.58 %
83.62 %
53.10 %
11.10 %
87.93 %
Market Capitalization
65.69 M
7.87 M
119.46 M
245.15 M
8.71 M
2.61 B
Price To Earning
0.64 X
(7.92) X
N/A
N/A
(5.22) X
(3.51) X
Price To Earnings To Growth
N/A
N/A
N/A
0.09 X
N/A
N/A
Price To Sales
1.60 X
20.38 X
1.80 X
2.80 X
0.92 X
28.68 X
Net Income
(63.59 M)
(164.57 M)
(93.8 M)
(108.3 M)
(25.95 M)
(444.04 M)
Earnings Per Share
(1.66) X
(3.07) X
(1.99) X
(1.73) X
(3.84) X
(1.48) X
Shares Owned By Insiders
7.27 %
1.37 %
0.95 %
19.29 %
1.66 %
0.52 %
Revenue
30 M
9.94 M
51.13 M
73.48 M
5.64 M
1.19 M
Working Capital
112.88 M
108.3 M
204.61 M
99.51 M
27.52 M
197.54 M
Cash And Equivalents
156.65 M
244.48 M
282.09 M
233.49 M
35.25 M
424.46 M
Cash Per Share
2.70 X
12.09 X
6.73 X
5.09 X
0.86 X
2.69 X
Gross Profit
(37 M)
14.88 M
15.11 M
13.35 M
766 K
N/A
Day Typical Price
0.95
0.28
2.89
3.45
1.6
8.45
Accumulation Distribution
0.0417
0.13
0.1
0.062
0.0898
0.0734
Market Facilitation Index
0.04
0.04
0.31
0.22
0.15
0.64
Daily Balance Of Power
0.75
0.75
(0.52)
0.4091
0.1333
0.4844
Period Momentum Indicator
0.03
0.03
(0.16)
0.09
0.02
0.31
Rate Of Daily Change
1.03
1.12
0.95
1.03
1.01
1.04
Day Median Price
0.94
0.28
2.93
3.44
1.6
8.4
Price Action Indicator
0.035
0.025
(0.20)
0.075
0.035
0.31
Relative Strength Index
52.93
30.8
58.72
45.48
45.93
82.3
Coefficient Of Variation
687.76
(3,287)
40232.04
(1,005)
(507.46)
(1,128)
Mean Deviation
3.2
7.03
3.24
4.3
3.83
3.21
Jensen Alpha
0.735
(0.59)
(0.12)
(0.76)
(1.12)
(0.65)
Total Risk Alpha
(0.06)
(2.70)
(0.70)
(1.51)
(1.89)
(1.05)
Sortino Ratio
0.1327
N/A
(0.03)
N/A
N/A
N/A
Downside Variance
14.66
N/A
13.75
N/A
N/A
N/A
Standard Deviation
4.39
14.33
4.45
5.82
5.31
4.23
Kurtosis
2.55
20.86
2.73
2.26
3.8
0.8937
Potential Upside
8.51
19.91
7.96
8.46
9.3
7.18
Treynor Ratio
(0.71)
(0.36)
0.0011
(0.41)
(1.98)
(0.18)
Maximum Drawdown
24.63
111.02
25.67
35.38
36.0
23.06
Variance
19.29
205.21
19.82
33.9
28.16
17.87
Market Risk Adjusted Performance
(0.70)
(0.35)
0.0111
(0.40)
(1.97)
(0.17)
Risk Adjusted Performance
0.1198
(0.01)
0.0102
(0.07)
(0.14)
(0.06)
Skewness
0.9539
(3.04)
1.09
(0.52)
1.08
(0.18)
Semi Deviation
3.13
N/A
3.51
N/A
N/A
N/A
Information Ratio
0.1156
(0.04)
(0.03)
(0.12)
(0.22)
(0.12)
Value At Risk
(5.05)
(15.48)
(6.43)
(9.47)
(6.91)
(6.95)
Expected Short fall
(4.16)
N/A
(4.12)
N/A
N/A
N/A
Downside Deviation
3.83
N/A
3.71
N/A
N/A
N/A
Semi Variance
9.81
N/A
12.33
N/A
N/A
N/A

Surface Oncology Competition Performance Charts

Five steps to successful analysis of Surface Oncology Competition

Surface Oncology's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Surface Oncology in relation to its competition. Surface Oncology's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Surface Oncology in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Surface Oncology's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Surface Oncology, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Surface Oncology position

In addition to having Surface Oncology in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Baby Boomer Prospects Thematic Idea Now

Baby Boomer Prospects
Baby Boomer Prospects Theme
Equities with large market capitalization that account for significant contribution to overall economic growth especially within dividend-paying instruments and stocks from healthcare and financial sectors. The Baby Boomer Prospects theme has 98 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Baby Boomer Prospects Theme or any other thematic opportunities.
View All  Next Launch
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.

Other Consideration for investing in Surface Stock

If you are still planning to invest in Surface Oncology check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Surface Oncology's history and understand the potential risks before investing.
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY